HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?

Results show a landmark change that could double survival rates in one of the most difficult oncology diagnoses, but there are still obstacles to overcome.

By PharmaVoice · Apr 29, 2026 · via PharmaVoice
Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
pipelineformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts
PipelineFierceBiotech ↗
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts
Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a…
Apr 28, 2026
Intellia’s Lonvo-z Becomes First In Vivo CRISPR Therapy to Reach FDA Doorstep
PipelineBriefing
Intellia’s Lonvo-z Becomes First In Vivo CRISPR Therapy to Reach FDA Doorstep
Intellia’s hereditary angioedema therapy cut swelling attacks by 87% in phase 3, positioning the biotech for t…
Apr 28, 2026
Veradermics wins at growing hair with oral Rogaine in first key test as a public company
PipelineEndpoints News ↗
Veradermics wins at growing hair with oral Rogaine in first key test as a public company
Veradermics has succeeded in its first major test as a newly-minted public company. The biotech's form of oral…
Apr 27, 2026